Alector, Inc.

Stocks

Market Closed - Nasdaq 04:00:00 2026-09-24 pm EDT			5-day change	1st Jan Change
1.920 ^USD	-4.95%		+3.78%	+23.08%

Sep. 16	Novartis halts ALS drug development after mid-stage trial failure	RE
Sep. 15	Alector, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM

Published on 09/22/2025 at 02:50 pm EDT - Modified on 09/22/2025 at 09:05 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, ladies and gentlemen, and welcome to Alector's conference call and webcast highlighting its progranulin franchise and Alector Brain

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

Sep. 16	Novartis halts ALS drug development after mid-stage trial failure	RE
Sep. 15	Alector, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM
Sep. 15	Alector, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02:10 PM
Aug. 06	Alector, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
Jul. 09	Wall Street Ignores the Sirens
Jul. 09	GSK adds Royal Philips' Chief Executive Jakobs to board	AN
Jul. 09	Oil keeps markets on edge
Jul. 09	UK Stocks-Factors to watch on July 9	RE
Jul. 08	Alector and GSK partnership to end after dementia, Alzheimer's drug failures	RE
Jul. 08	Alector, Inc. Announces Termination of Collaboration Agreement with Glaxo Wellcome UK Limited	CI
Jul. 08	Alector LLC and Alector, Inc. Repay $10,428,827.77 Aggregate Principal Amount Of Loans Under Loan And Security Agreement With Hercules Capital, Inc	CI
May. 07	Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
May. 05	Alector, Inc. - Special Call
Apr. 29	Alector to discontinue phase 2 trial of nivisnebart	RE
Apr. 29	Alector Inc Discontinues Phase 2 Progress-Ad Trial of Nivisnebart and Provides Pipeline Update	CI

Duration

Period

Sector